Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axsome Therapeutics, Inc.AXSM · Entity 2469 | Vice President, Finance | March 15, 2017 | March 17, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axsome Therapeutics, Inc.
Report date March 15, 2017 · Filed March 17, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.95 · Expires 2027-03-14 | Direct | 25,000 |
Reported balance
After 2017-03-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-03-15 · Grant · Acquired 25,000 · Balance 25,000 F1: The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on March 15, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on March 15, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 15, 2017 Filed Mar 17, 2017 17:00 UTC | Axsome Therapeutics, Inc. AXSM · Entity 2469 | GrantEmployee Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $4.95 | $0.00 |
DisclosureSEC source: 0001104659-17-017643 · a4.xml · derivative · entry 1 Ames Constance · CIK 0001658296 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-03-14 F1 · derivative.exercise_date: The option will vest in substantially equal quarterly installments over four years such that the option will be fully vested on March 15, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.